Home > Result Summaries: Compounds > H1n1 Pandemic Influenza Vaccine

Result Summaries: H1n1 Pandemic Influenza Vaccine

Result Summaries for H1n1 Pandemic Influenza Vaccine
GSK
Study ID		 Phase Title Summary (Download)
113440 Phase 2 A study to evaluate the safety and immunogenicity of A/California/7/2009 (H1N1)v-like vaccines GSK2340273A and GSK2340274A in adults aged 18 years and older (0 citation(s)) Click here to download result summary.
113456 Phase 3 Safety and immunogenicity study of GSK Biologicals’ influenza vaccine GSK2340272A in adults aged 18 to 60 years (0 citation(s)) Click here to download result summary.
113459 Phase 3 Safety and immunogenicity study of GSK Biologicals’ influenza vaccine GSK2340272A in adults aged 18 years and above (0 citation(s)) Click here to download result summary.
113462 Phase 2 Safety and immunogenicity study of GSK Biologicals’ pandemic influenza candidate vaccine (GSK2340272A) in children aged 6 to 35 months (0 citation(s)) Click here to download result summary.
113482 Phase 2 A study to evaluate the safety and immunogenicity of A/California/7/2009 (H1N1)v-like vaccines GSK2340274A and GSK2340273A in children 6 months to less than 9 years of age (0 citation(s)) Click here to download result summary.
113519 Phase 2 Immunogenicity and safety study of GSK Biologicals’ influenza candidate vaccine GSK2340274A (0 citation(s)) Click here to download result summary.
113525 Phase 2 Immunogenicity, safety and reactogenicity of GSK Biologicals’ influenza GSK2340272A and Fluarix™ 2009-2010 vaccines when co-administered in elderly subjects aged 61 years and older (0 citation(s)) Click here to download result summary.
113528 Phase 3 Safety and immunogenicity study of GSK Biologicals’ pandemic influenza candidate vaccine (GSK2340272A) in children aged 3 to 17 years (0 citation(s)) Click here to download result summary.
113535 Phase 3 Immunological equivalence between GSK2340272A and GSK2340274A influenza vaccines in adults aged 18 to 60 years (0 citation(s)) Click here to download result summary.
113572 Phase 3 Immunogenicity and safety of GSK Biologicals’ pandemic influenza candidate vaccine GSK2340272A (0 citation(s)) Click here to download result summary.
113574 Phase 2 Safety and Immunogenicity Study of GSK Biologicals' Influenza Vaccine GSK2340272A in Adults Aged 18 to 60 Years (1 citation(s)) Click here to download result summary.
113630 Phase 3 Safety and immunogenicity study of GSK Biologicals’ influenza vaccine GSK2340272A in adults aged 18 years and above (0 citation(s)) Click here to download result summary.
113638 Phase 3 Safety and immunogenicity study of GSK Biologicals’ pandemic influenza candidate vaccine (GSK2340272A) in children aged 3 to 17 years (0 citation(s)) Click here to download result summary.
113809 Phase 3 Immunological non-inferiority between two process-manufactured influenza vaccines in adults aged 18 to 60 years (0 citation(s)) Click here to download result summary.
113847 Phase 2 Safety and immunogenicity study of GSK Biologicals’ pandemic influenza (H1N1) candidate vaccine (GSK2340274A) in Japanese children aged 6 months to 17 years (0 citation(s)) Click here to download result summary.
113866 Phase 3 Safety and immunogenicity study of GSK Biologicals’ influenza vaccine GSK2340272A in adults aged 18 to 60 years (0 citation(s)) Click here to download result summary.

Filter list by: